| Metric | Value | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue | 79.45 Cr | 8.9% | 19.6% |
| Total Income | 84.14 Cr | 4.6% | 2.4% |
| Expenditure | 67.68 Cr | 0.3% | 0.3% |
| PBT | 16.46 Cr | 28.6% | 11.9% |
| Net Profit | 14.22 Cr | 43.2% | 11.0% |
| OPM | 18.88% | 6.54pp | 12.96pp |
| NPM | 16.90% | 4.56pp | 1.32pp |
| EPS | 0.26 | 44.4% | 13.0% |
Solid rebound, hedged growth — execution vs. ambition
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Q1 numbers corroborate guidance given on call. No formal FY27 revenue target stated previously; management is maintaining stance, not raising. Track record on backlog/execution appears sound.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 validates turnaround: 19.7% revenue growth, 4x EBITDA recovery, 184.8 Cr cash. But management deliberately hedges growth expectations (high-single to double-digit aspiration, not commitment), Middle East faces 1-2 month order delays, and PAT growth (11% YoY) lags revenue sharply. Long-term vision compelling (GenAI, satellites, data centers) but execution risk remains; near-term is steady-state, not momentum.
₹79.5 Cr
Revenue · +19.7% YoY₹14.2 Cr
Reported PAT · +11% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Revenue grew 8.9% QoQ and 19.7% YoY
METDelivered: 79.5 Cr (vs 72.96 Q4 FY26, vs 66.4 Q1 FY26)
EBITDA grown fourfold YoY; margin at 21.2%
MET16.87 Cr EBITDA (21.2% of 79.45 confirmed); Q1 FY26 EBITDA ~4 Cr inferred
PAT stood at 17.9% margin (14.22 Cr)
MET14.22/79.45 = 17.9%; delivered NPM discrepancy (stated 16.9% vs 17.9% calculated)
70% revenue recurring, 30% new order intake annually
UnverifiedNo independent verification; mgmt structural model, not contradicted by delivered results
Middle East slowdown: 1-2 month contract closure delays, no cancellations
METQualitative; confirmed in Q&A; some contracts mentioned moved from Q1 to Q2/Q3
Earnings quality
What changed since the last call
Growth tone: bullish → cautious
DowngradePrior call stated 'very bullish' outlook, 24% order intake uplift. This call: aspirational double-digit, realistic high-single digits. No formal FY27 target stated; management resisting analyst pressure for specific guidance.
Middle East risk materialized
Downgrade1-2 month delays confirmed in legal/contract closures. Prior uncertainty; now acknowledged slowdown (no cancellations). Mitigation: moved delivery on-site staff to Bangalore.
Margin philosophy: expand → maintain & reinvest
NeutralPrior implicit push for margin expansion; now explicit: stable mid-to-high teens, reinvest excess into R&D. CEO: 'not to maximize short-term margins' but 'long-term shareholder value.'
Product portfolio: RAFM-centric → multi-pillar
UpgradeEmphasis on Partner Ecosystem Management (PEM) gaining traction; FraudZap investment recovered. New fraud types (ATO, social engineering) becoming focus areas.
The Q&A
Moderate. Analysts pressed for specific guidance on funnel size, growth trajectory, 100-Cr milestone, margin targets. Management deflected on competitive grounds but acknowledged investor expectations (double-digit growth from NDR feedback). No hostile tone; structured evasion on sensitive metrics.
Growth guidance — Patrick Mathias, Individual Investor (15-year holder)
DodgedQualified pipeline is 3-4x of order intake target (no specific size disclosed). 70% revenue recurring each year, 30% new wins. Publicly announced deals last year were 18-20 million; actual pipeline larger. Cannot disclose specific funnel size due to competitive sensitivity.
Growth trajectory — Patrick Mathias, Individual Investor
PartialWe are on trajectory of growth, trending near double-digit this year. Will I deliver double-digit or high single digits? Remains to be seen. Aspiration is bigger; reality-grounded. NDR feedback: double-digit growth expected by investors. Rules of disclosure prevent forward guidance in earnings calls.
Margin sustainability — Harshit Singhania, Robo Capital
AnsweredMargins should be in this ballpark (mid-to-high teens). We have expanded from prior year; won't cap margins as we grow, but will reinvest margin excess into R&D and product development. Not maximizing short-term margins; aiming for healthy profile + growth investments.
Order execution delays — Sanjyot Khare, Individual Investor
AnsweredSome slowdown in Middle East; no cancellations. Delays are 1-2 months, not quarter-scale. Root cause: legal scrutiny, liability negotiations (LOLs). Delays in APAC as well. US/Europe stable. No major deals lost; just shifted timelines. Comfortable delaying by month for watertight contracts.
Contract-to-revenue cycle — Abhishek Kale, Individual Investor
AnsweredTypically 4-5 quarters (sign → implement → go-live → recognize). Goal is reduce by 1 quarter (to 3-4). Recent project delivered 45 days early. On average gaining 1-1.5 months per project. Working on reusability, libraries, standardization to crash timeline further.
Long-term strategy — Nandagopal B, Individual Investor
AnsweredCurrent split: ensure products GenAI-enabled (H1), enter high-growth CapEx markets like data centers & satellites (H2/H3), expand fraud portfolio into new types (ATO, social engineering). Goal: transition to 60% H1, 30% H2, 10% H3 split. Telco is cash cow; ride new waves (satellites, data centers). Need to catch a wave to ride it.
Investor communications — Mahesh Kumar, Individual Investor
AnsweredInstead of one annual Investor Day, we're doing quarterly NDRs in Mumbai, Ahmedabad, Chennai. Will invite existing shareholders. Investors prefer NDRs for deeper discussion. We'll come to your cities.
Litigation status — Jitendra Bhutoria, Individual Investor
AnsweredSectoral contract: still litigating outside India (Middle East jurisdiction, slower systems). One of 3 entities settled; two pending. Hoping Q2 closure. Middle East subsidiary: self-sufficient now, no fresh capital needed currently (but volatile region, visibility limited).
Guidance
Aspiration: double-digit growth FY27; realistic: high-single to double-digit
LowCEO explicitly non-committal. NDR feedback suggests market expects double-digit. No formal FY27 revenue target given. Q1 showed 19.7% YoY; deceleration possible if order intake slows.
Margins stable at mid-to-high teens (21.2% EBITDA demonstrated); won't expand aggressively
HighClear policy stated: maintain healthy margin profile, reinvest excess into R&D (engineering + AI engineering). Won't maximize short-term margins. Confidence high based on structural cost controls and pricing thresholds by geography.
R&D intensity to increase (people expense replaced by token/AI spend); ESOP buyback 2% FY27, structured over quarters
MediumR&D density to rise to fund H2/H3 bets (satellites, data centers, new fraud types). Core R&D team 200 of 700 headcount; expect growth. ESOP execution expected Q3 FY27 onward (postal ballot underway).
Risks the call surfaced
Customer concentration
MediumNo segment breakdown by customer provided. Implied Tier-1 operator in Middle East is material (renewed; slowdown occurring). Loss of any Tier-1 would hurt. No explicit diversification plan stated.
Geographic macro risk (Middle East)
MediumWar in Middle East causing 1-2 month delays in contract closures, legal/liability scrutiny heightened. Some slowdown in order intake but no cancellations yet. Macro escalation could shift to cancellations.
Revenue recognition timeline risk
MediumTypical 4-5 quarters from signing to subscription revenue recognition. Delays in legal closures (1-2 months) push revenue further out. Revenue timing uncertainty increases if order intake falters.
PAT growth lagging revenue growth
LowRevenue +19.7% YoY; PAT +11% YoY. 8.7 percentage point gap suggests margin headwind. Attributed to R&D reinvestment (rising headcount, token spend) and FX loss (~3 Cr). Sustainable if intentional; risk if involuntary.
Litigation tail risk (sectoral contracts)
LowSectoral contracts written off historically; now in litigation. One of three entities settled; two pending. Court systems moving slowly in Middle East jurisdiction. Timeline unclear but mgmt hopeful by end FY27.
Management
Score 6/10. Clear on operational metrics (backlog, renewal activity), evasive on competitive sensitivities (funnel size, margin thresholds, RFP pricing). CEO actively engages but deflects with 'industry comps' and 'competitive disclosure rules' when pressed. Candid on Middle East risks but avoids quantification. Strong on delivery: Q1 met stated metrics (19.7% YoY, 21.2% EBITDA margin, cash build). Backlog execution improving. Order execution delays (1-2 months) acknowledged but not seen as systemic. Track record shows discipline (cost controls, billing discipline).
1 · Q2 FY27
ESOP execution begins (2% buyback authorized, 5% approved). Fair market valuation of ID Central investment markup.
2 · Q3 FY27
ESOP allocation to employees (6-month window post-buyback). Structural balance-sheet changes (capital adjustment) to be proposed.
3 · Sep 2026 onward
Litigation settlement closures expected (sectoral contracts). Three entities involved; one settled, two pending. Material legal resolution.
Long-term vision compelling (GenAI, satellites, data centers) but execution risk remains; near-term is steady-state, not momentum.
Turnaround Durable, But Growth Guidance Hedged — Where Profit Lags Revenue
Revenue grew 19.7% YoY to ₹79.5 Cr, but PAT limped to just 11% growth at ₹14.2 Cr — an 8.7-point lag that signals either margin compression or deliberate R&D burn. Management's tone shifted from prior 'very bullish' to cautiously optimistic, with Middle East delays now real and no formal FY27 revenue target in sight.
₹79.5 Cr
+19.7% YoY, +8.9% QoQ
₹14.2 Cr
+11% YoY (vs +19.7% revenue)
₹16.87 Cr
21.2% margin, ~4x YoY
₹184.8 Cr
Fortress balance sheet
The core tension: profit growth lags revenue by 8.7 points
On the surface, Subex delivered a solid quarter: revenue at ₹79.5 Cr (+19.7% YoY) validates the turnaround narrative, and EBITDA margin at 21.2% shows a fourfold recovery from Q1 FY26's anaemic base. But PAT grew only 11% YoY, leaving an 8.7-point gap versus revenue growth. This is not a rounding error — it signals either structural margin compression or deliberate reinvestment in R&D that is yet to prove its ROI.
Where the PAT shortfall came from
Management attributes the gap to three headwinds: (1) a ~₹3 Cr foreign exchange loss (rupee weakness), (2) salary cycle timing — Q1 typically carries higher payroll expenses, and (3) deliberate investment in R&D and AI engineering to fuel next-phase growth. The normalized PAT (before ₹1.87 Cr in exceptional items) stood at ₹16.09 Cr, or 20.2% margin — stronger than reported, but still a softer underlying profit growth story than the headline revenue number suggests.
Management's claims: which held up
Revenue grew 8.9% QoQ and 19.7% YoY
Supported₹79.5 Cr this quarter vs ₹72.96 Cr Q4 FY26, vs ₹66.4 Cr Q1 FY26. Math checks.
EBITDA expanded fourfold YoY; margin at 21.2%
Supported₹16.87 Cr EBITDA confirmed at 21.2% of revenue. Q1 FY26 base ~₹4 Cr inferred. Fourfold claim holds.
PAT margin at 17.9% (₹14.22 Cr)
Supported14.22 ÷ 79.45 = 17.9%. Delivered. (Note: stated NPM of 16.9% is discrepancy in rounding.)
70% revenue is recurring; 30% from new order intake annually
UnverifiedStructural claim, not independently verified against results. Not contradicted by delivered numbers.
Middle East: 1-2 month contract delays, no cancellations
SupportedConfirmed in Q&A. Some contracts shifted from Q1 to Q2/Q3. No deal losses reported.
Order pipeline is 3-4x of annual order intake target
UnverifiedDisclosed on call but specific funnel size withheld (competitive sensitivity cited). No contradiction.
What changed on this call versus the prior quarter
Growth tone downshifted: 'Very bullish' outlook → 'Aspirational double-digit, realistic high-single digits'
Middle East risk materialized: Abstract geopolitical uncertainty → Concrete 1-2 month order delays (no cancellations yet)
Margin philosophy clarified: Implicit expansion focus → Explicit: 'Maintain mid-to-high teens, reinvest excess into R&D' (not maximizing near-term margins)
How the street is reading this: price, flows, and sentiment
Subex trades at ₹13.88 as of August 14, 2026 — a bullish trend holding above its 20-day (₹13.04), 50-day (₹12.28), and 200-day (₹10.93) moving averages. The stock is near its all-time high of ₹14.4 but has given back 3.61%, suggesting post-results profit-taking. RSI at 67.6 is in neutral territory, not stretched overbought. The concerning signal: FII holdings declined 51 basis points QoQ to 0.59% (from 1.10% in Q4), while DII and promoter stakes remain flat. Despite the bullish trend, foreign institutional investors are trimming exposure — a subtle warning that the turnaround narrative, while validated, is already priced in and the growth hedging is pushing them to the exits.
Volume is normal; no evidence of panic selling or institutional capitulation. But the FII reduction is a yellow flag: the street's own 51bp vote of no-confidence in near-term growth acceleration.
EBITDA recovered fourfold YoY; margin at 21.2% shows pricing power and cost discipline
Cash fortress at ₹184.8 Cr provides strategic flexibility (ESOP, M&A, R&D investment)
Customer renewals across all geographies validate product moats and customer stickiness
70% recurring revenue base provides stability; 30% new order intake drives growth
PAT growth (11% YoY) lags revenue (19.7%) by 8.7 points; margin compression or R&D burn emerging
Management tone pullback: 'Very bullish' → hedged. No formal FY27 revenue target committed.
Middle East order delays (1-2 months) are now real; escalation risk if regional tensions persist
FII allocation trimmed 51bp QoQ despite bullish trend; smart money taking profit
New product/segment traction (PEM, FraudZap) validates diversification strategy
R&D reinvestment (200/700 headcount, GenAI focus) positions for long-term growth, but ROI unproven in near term
Ranked risks: what should concern a holder
PAT growth (11%) lagging revenue (19.7%) — is it R&D investment or margin erosion?
MediumIf margin compression is involuntary (rising labor costs, pricing pressure, FX headwinds), it signals structural profit headwinds. If it's voluntary R&D investment, ROI must materialize within 2-3 quarters or shareholder returns erode.
Middle East macro uncertainty: 1-2 month order delays could escalate to cancellations if regional tensions worsen
MediumManagement acknowledges delays but not cancellations to date. If conflicts escalate, this region (implied material % of revenue) could face sharp contraction. No mitigation disclosed beyond moving staff to Bangalore.
Customer concentration: Top 5 likely represent >50% of revenue; no segment granularity disclosed
MediumLoss of any Tier-1 customer would create sharp revenue cliff. Renewals are happening (Tier-1 Middle East, Europe, APAC confirmed), but concentration risk is high and undisclosed.
Revenue recognition timeline (4-5 quarters sign → subscribe) extends visibility; legal delays elongate this further
MediumIf order intake slows, revenue will feel the impact 1.5 years later. Current backlog is the only near-term buffer. No specific backlog quantum disclosed (competitive sensitivity cited).
No formal FY27 revenue target committed; guidance remains 'aspirational' — leaves investor visibility gap
Low-to-MediumAmbiguity allows management flexibility but frustrates growth-focused investors. Street expects double-digit growth (per NDR feedback); management will realistic (high-single digit aspirational). If actuals miss, stock could re-rate.
Litigation tail on sectoral contracts (Middle East jurisdiction); one of three entities settled, two pending
LowSettlement proceeds, if any, could be material to cash flow, but timeline is vague ('hoping before FY27 end'). Not factored into near-term guidance.
Execution risk on new markets (satellites, data centers, AI-enabled fraud detection): unproven adjacencies, different GTM
Low-to-MediumStrategic vision is compelling (ride new waves), but these markets require different skill sets, partner ecosystems, and sales models. Capital and management time diverted from core telco strength if execution falters.
What to watch next: the three drivers of re-rating
1 · Q2 PAT growth trajectory — is the 11% lag sustainable?
If Q2 reported PAT also grows in low-teens while revenue stays in mid-to-high teens, the margin compression narrative hardens and R&D ROI concerns deepen. If PAT growth accelerates toward revenue growth (even reaching mid-teens), management's thesis holds. This is the single most important metric.
2 · Middle East order execution — do the 1-2 month delays resolve in H2?
Will H2 FY27 (Oct-Mar) show acceleration as Q1/Q2-delayed contracts close? Or will delays persist and new cancellations surface? If the region returns to normal order velocity, confidence in ₹100 Cr quarterly revenue aspiration strengthens. If delays widen, growth visibility collapses.
3 · Management commitment on FY27 growth — will a specific revenue target be disclosed?
Will management commit to a quantified FY27 revenue milestone before the year-end NDR circuit, or remain vague? Institutional re-entry (FII allocation has fallen 51bp) hinges on clarity. Ambiguity perpetuates caution.
The honest read: steady state, not acceleration
Subex's Q1 FY27 validates the turnaround: a fourfold EBITDA recovery, ₹184.8 Cr in cash, customer renewals across geographies, and a structural 70%-recurring revenue base all point to a durable business. But the quarter also signals a shift from turnaround to steady state. Revenue growth at 19.7% is solid in absolute terms; PAT growth at 11% shows the profit upside is constrained by R&D reinvestment and FX headwinds.
Management's tone pullback — from prior 'very bullish' to 'aspirational double-digit, realistic high-single digits' — is the candid signal. No formal FY27 revenue target has been committed. Middle East delays (1-2 months, no cancellations yet) introduce execution risk. FII allocations have trimmed 51bp QoQ, a subtle vote of no-confidence in near-term growth acceleration.
This is not a broken story or a red flag for holders. It is a mature turnaround settling into disciplined execution. The company is choosing to invest in long-term positioning (AI, new markets) over maximizing near-term profit — a sound strategic choice but one that will not excite momentum investors. Subex trades at ₹13.88, within 3.6% of its all-time high, and near consensus fair value for a 'Hold' rating.
The number to track from here: Quarterly PAT growth versus revenue growth. If the gap widens further, R&D ROI is questionable and margins are eroding. If it narrows, management's reinvestment thesis is proving out and the long-term value case strengthens. The next 1–2 quarters will resolve that debate.